{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T21:48:25Z","timestamp":1781300905170,"version":"3.54.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005612","name":"shionogi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005612","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Klin Intensivmed Notfmed"],"published-print":{"date-parts":[[2023,3]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title><jats:sec>\n                <jats:title>Hintergrund<\/jats:title>\n                <jats:p>Infektionen mit antibiotikaresistenten Bakterien stellen eine hohe Gesundheitsbelastung dar, da sie mit erh\u00f6hter Letalit\u00e4t assoziiert sind und l\u00e4ngerfristige dramatische Beeintr\u00e4chtigungen der Lebensqualit\u00e4t hervorrufen k\u00f6nnen. In Deutschland erkranken j\u00e4hrlich etwa 54.500\u00a0Menschen an Infektionen durch antibiotikaresistente Erreger, von denen etwa 2400\u00a0Menschen versterben. Infektionen mit multiresistenten gramnegativen Bakterien (MRGN), insbesondere mit carbapenemresistenten Erregern, stellen ein besonderes Risiko dar, da nur eine begrenzte Zahl an Therapieoptionen verf\u00fcgbar ist.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Fragestellung<\/jats:title>\n                <jats:p>Wie sind die Ergebnisse aus Studien und Compassionate-Use-Programm mit dem neuen Siderophorantibiotikum Cefiderocol, das im April 2020 von der Europ\u00e4ischen Arzneimittel-Agentur (EMA) bei Erwachsenen zur Behandlung von Infektionen durch aerobe gramnegative Erreger zugelassen wurde, wenn nur begrenzte Behandlungsm\u00f6glichkeiten zur Verf\u00fcgung stehen? Die Zulassung ist pathogenbasiert und fokusunabh\u00e4ngig [5].<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Ergebnisse<\/jats:title>\n                <jats:p>Cefiderocol, das \u00fcber einen innovativen Zelleintrittsmechanismus verf\u00fcgt, ist als erstes \u03b2\u2011Laktam-Antibiotikum aus der Gruppe der Cephalosporine stabil gegen\u00fcber allen klinisch relevanten \u03b2\u2011Laktamasen, einschlie\u00dflich Carbapenemasen, und hat eine hohe In-vitro-Wirksamkeit gegen\u00fcber carbapenemresistenten MRGN. Die Ergebnisse werden durch klinische Studien bei komplizierten Harnwegsinfektionen, nosokomialer Pneumonie\/Beatmungspneumonie und schweren Infektionen durch carbapenemresistente Erreger best\u00e4tigt.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Fazit<\/jats:title>\n                <jats:p>Klinische Studiendaten sowie die Ergebnisse aus den weltweiten Erfahrungsberichten zeigen, dass Cefiderocol eine vielversprechende Behandlungsoption f\u00fcr schwere Infektionen durch multiresistente, insbesondere carbapenemresistente gramnegative Bakterien darstellt.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00063-022-00925-5","type":"journal-article","created":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T14:08:05Z","timestamp":1659362885000},"page":"149-155","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Klinische Erfahrungen mit Cefiderocol","Clinical experience using cefiderocol"],"prefix":"10.1007","volume":"118","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1019-1301","authenticated-orcid":false,"given":"Oliver","family":"Witzke","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thorsten","family":"Brenner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,8,1]]},"reference":[{"key":"925_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(20)30796-9","author":"M Bassetti","year":"2020","unstructured":"Bassetti\u00a0M, Echols\u00a0R et\u00a0al (2020) Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a\u00a0randomised, open-label, multicentre, pathogen-focused, descriptive, phase\u00a03 trial. Lancet. https:\/\/doi.org\/10.1016\/S1473-3099(20)30796-9","journal-title":"Lancet"},{"issue":"9","key":"925_CR2","first-page":"1900123","volume":"24","author":"A Brolund","year":"2019","unstructured":"Brolund\u00a0A, EURGen-Net capacity survey group (2019) Worsening epidemiological situation of carbapenemase-producing Enterobacteriaceae in Europe, assessment by national experts from 37\u00a0countries, July 2018. Eur Commun Dis Bull 24(9):1900123","journal-title":"Eur Commun Dis Bull"},{"issue":"10","key":"925_CR3","doi-asserted-by":"publisher","first-page":"e01076-18","DOI":"10.1128\/AAC.01076-18","volume":"62","author":"K Bush","year":"2018","unstructured":"Bush\u00a0K (2018) Past and present perspectives on \u03b2-lactamases. Antimicrob Agents Chemother 62(10):e01076-18. https:\/\/doi.org\/10.1128\/AAC.01076-18","journal-title":"Antimicrob Agents Chemother"},{"key":"925_CR4","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/S1473-3099(18)30605-4","volume":"19","author":"A Cassini","year":"2019","unstructured":"Cassini\u00a0A, Diaz-H\u00f6gberg\u00a0L et al (2019) Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: a\u00a0population-level modelling analysis. Lancet Infect Dis 19:56\u201366","journal-title":"Lancet Infect Dis"},{"key":"925_CR5","unstructured":"Cefiderocol-Fachinformation Stand April 2020"},{"issue":"5","key":"925_CR6","doi-asserted-by":"publisher","first-page":"ofaa150","DOI":"10.1093\/ofid\/ofaa150","volume":"7","author":"M Dagher","year":"2020","unstructured":"Dagher\u00a0M, Ruffin\u00a0F et\u00a0al (2020) Case report: successful rescue therapy of extensively drug resistent (XDR) Acinetobacter baumanni osteomyelitis with cefiderocol. Open Forum Infect Dis 7(5):ofaa150. https:\/\/doi.org\/10.1093\/ofid\/ofaa150","journal-title":"Open Forum Infect Dis"},{"issue":"7","key":"925_CR7","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.1093\/jac\/dkaa117","volume":"75","author":"M Delgado-Valverde","year":"2020","unstructured":"Delgado-Valverde\u00a0M (2020) Activity of cefiderocol against high-risk clones of multidrug-resistant enterobacterales, acinetobacter baumannii, pseudomonas aeruginosa and Stenotrophomonas maltophilia. J\u00a0Antimicrob Chemother 75(7):1840\u20131849","journal-title":"J Antimicrob Chemother"},{"issue":"S7","key":"925_CR8","doi-asserted-by":"publisher","first-page":"S565","DOI":"10.1093\/cid\/ciz830","volume":"69","author":"Y Doi","year":"2019","unstructured":"Doi\u00a0Y (2019) Treatment options for carbapenem-resistant Gramnegative bacterial infections. Clin Infect Dis 69(S7):S565\u2013S575","journal-title":"Clin Infect Dis"},{"key":"925_CR9","unstructured":"https:\/\/www.rki.de\/DE\/Content\/Infekt\/Antibiotikaresistenz\/Uebersichtsbeitraege\/AMR_Europa.html. Zugegriffen: 1. Feb. 2022"},{"issue":"2","key":"925_CR10","doi-asserted-by":"publisher","first-page":"e01968-17","DOI":"10.1128\/AAC.01968-17","volume":"62","author":"MA Hackel","year":"2018","unstructured":"Hackel\u00a0MA et\u00a0al (2018) In vitro activity of the siderophore cephalosporin, cefiderocol, against carbapenem-nonsusceptible and multidrug-resistant isolates of gram-negative bacilli collected worldwide in 2014 to 2016. Antimicrob Agents Chemother 62(2):e01968-17","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"925_CR11","doi-asserted-by":"publisher","first-page":"7396","DOI":"10.1128\/AAC.01405-16","volume":"60","author":"A Ito","year":"2016","unstructured":"Ito\u00a0A, Nishikawa\u00a0T et\u00a0al (2016) Siderophore cephalosporin cefiderocol utilizes ferric iron transporter systems for antibacterial activity against pseudomonas aeruginosa. Antimicrob Agents Chemother 60(12):7396\u20137401","journal-title":"Antimicrob Agents Chemother"},{"key":"925_CR12","doi-asserted-by":"publisher","first-page":"649","DOI":"10.3390\/antibiotics10060649","volume":"10","author":"C K\u00f6nig","year":"2021","unstructured":"K\u00f6nig\u00a0C, Wichmann\u00a0D et al (2021) Cefiderocol in critically ill patients with multi-drug resistant pathogens: real-life data on pharmacokinetics and microbiological surveillance. Antibiotics 10:649. https:\/\/doi.org\/10.3390\/antibiotics10060649","journal-title":"Antibiotics"},{"key":"925_CR13","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1016\/S1473-3099(19)30403-7","volume":"19","author":"MH Kollef","year":"2019","unstructured":"Kollef\u00a0MH, Novacek\u00a0M et al (2019) Ceftolozane\u2013tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): a\u00a0randomised, controlled, double-blind, phase 3, non-inferiority trial. Lancet Infect Dis 19:1299\u20131311","journal-title":"Lancet Infect Dis"},{"key":"925_CR14","volume-title":"Comparison of 28-day mortality rates of recently completed prospective, randomized treatment studies of adult patients with carbapenem-resistant Gram-negative bacterial infections","author":"T Lodise","year":"2020","unstructured":"Lodise\u00a0T, Bassetti\u00a0M et al (2020) Comparison of 28-day mortality rates of recently completed prospective, randomized treatment studies of adult patients with carbapenem-resistant Gram-negative bacterial infections. ECCMID A2497."},{"key":"925_CR15","volume-title":"Post-hoc analysis of the clinical and microbiological outcomes for Cefiderocol against Carbapenem-resistant Non-fermentative Gram negative bacteria in the CREDIBLE-CR study","author":"C Longshaw","year":"2020","unstructured":"Longshaw\u00a0C, Santerre Henriksen\u00a0A (2020) Post-hoc analysis of the clinical and microbiological outcomes for Cefiderocol against Carbapenem-resistant Non-fermentative Gram negative bacteria in the CREDIBLE-CR study. Presented at BSAC Gram-negative infection management meeting."},{"key":"925_CR16","series-title":"ID Week: LB4","volume-title":"Efficacy and safety of cefiderocol vs. high-dose meropenem in patients with nosocomial pneumonia\u2014results of a\u00a0phase 3, randomized, multicenter, double-blind, non-inferiority study","author":"TD Nagata","year":"2019","unstructured":"Nagata\u00a0TD, Wunderink et al (2019) Efficacy and safety of cefiderocol vs. high-dose meropenem in patients with nosocomial pneumonia\u2014results of a\u00a0phase 3, randomized, multicenter, double-blind, non-inferiority study. ID Week: LB4"},{"issue":"4","key":"925_CR17","doi-asserted-by":"publisher","first-page":"dlab174","DOI":"10.1093\/jacamr\/dlab174","volume":"3","author":"R Pascale","year":"2021","unstructured":"Pascale\u00a0R, Pasquini\u00a0Z, Bartoletti\u00a0M et al (2021) Cefiderocol treatment for carbapenem-resistant Acinetobacter baumannii infection in the ICU during the COVID-19 pandemic: a\u00a0multicentre cohort study. JAC Antimicrob Resist 3(4):dlab174. https:\/\/doi.org\/10.1093\/jacamr\/dlab174","journal-title":"JAC Antimicrob Resist"},{"key":"925_CR18","first-page":"A2000","volume-title":"Report of the national reference centre for multidrug-resistant Gram-negative bacteria on carbapenemases in Germany in 2019","author":"N Pfennigwerth","year":"2020","unstructured":"Pfennigwerth\u00a0N (2020) Report of the national reference centre for multidrug-resistant Gram-negative bacteria on carbapenemases in Germany in 2019. ECCMID 2020,, S A2000"},{"key":"925_CR19","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1016\/S1473-3099(18)30554-1","volume":"18","author":"S Portsmouth","year":"2018","unstructured":"Portsmouth\u00a0S, van Veenhuyzen\u00a0D et al (2018) Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a\u00a0phase 2, randomised, double-blind, non-inferiority trial. Lancet Infect Dis 18:1319\u20131328","journal-title":"Lancet Infect Dis"},{"issue":"5","key":"925_CR20","doi-asserted-by":"publisher","first-page":"e01955","DOI":"10.1128\/AAC.01955-19","volume":"64","author":"KVI Rolston","year":"2020","unstructured":"Rolston\u00a0KVI, Gerges\u00a0B, Shekburne\u00a0S et\u00a0al (2020) Activity of cefiderocol and comparators against isolates from cancer patients. Antimicrob Agents Chemother 64(5):e1955","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"925_CR21","doi-asserted-by":"publisher","first-page":"ofz149","DOI":"10.1093\/ofid\/ofz149","volume":"6","author":"A Torres","year":"2019","unstructured":"Torres\u00a0A, Rank\u00a0D et al (2019) Randomized trial of ceftazidime-avibactam vs meropenem for treatment of hospital-acquired and ventilator-associated bacterial pneumonia (REPROVE): analyses per US FDA\u2013specified end points. Open Forum Infect Dis 6(4):ofz149","journal-title":"Open Forum Infect Dis"},{"key":"925_CR22","volume-title":"DIVI, 4.\u20136.12.2019, Hamburg","author":"T Welte","year":"2019","unstructured":"Welte\u00a0T (2019) Therapieoptionen bei multiresistenten gramnegativen Erregern\u00a0\u2013 Licht am Ende des Tunnels. In: DIVI, 4.\u20136.12.2019, Hamburg"},{"key":"925_CR23","unstructured":"World Health Organization Global priority list of antibiotic-resistant bacteria to guide research, discovery and development of new antibiotics. https:\/\/www.who.int\/medicines\/publications\/WHO-PPL-Short_Summary_25Feb-ET_2019. Zugegriffen: 1. Feb. 2022"},{"issue":"2","key":"925_CR24","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/S1473-3099(20)30731-3","volume":"21","author":"RG Wunderink","year":"2021","unstructured":"Wunderink\u00a0RG, Matsunaga\u00a0Y et\u00a0al (2021) Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a\u00a0randomised, double-blind, phase\u00a03, non-inferiority trial. Lancet Infect Dis 21(2):213\u2013225. https:\/\/doi.org\/10.1016\/S1473-3099(20)30731-3","journal-title":"Lancet Infect Dis"},{"issue":"3","key":"925_CR25","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s40265-019-1055-2","volume":"79","author":"GG Zhanel","year":"2019","unstructured":"Zhanel\u00a0GG, Golden\u00a0AR et al (2019) Cefiderocol: a\u00a0siderophore cephalosporin with activity against carbapenem-resistant and multidrug-resistant gram-negative Bacilli. Drugs 79(3):271\u2013289","journal-title":"Drugs"},{"issue":"6","key":"925_CR26","doi-asserted-by":"publisher","first-page":"ofaa185","DOI":"10.1093\/ofid\/ofaa185","volume":"7","author":"S Zingg","year":"2020","unstructured":"Zingg\u00a0S, Nicoletti\u00a0GJ et al (2020) Cefiderocol for extensively drug-resistant gram-negative bacterial infections: real-world experience from a\u00a0case series and review of the literature. Open Forum Infect Dis 7(6):ofaa185","journal-title":"Open Forum Infect Dis"},{"key":"925_CR27","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1093\/ofid\/ofaa439.1498","volume":"7","author":"T Katsube","year":"2020","unstructured":"Katsube\u00a0T, Kawaguchi\u00a0N, Matsunaga\u00a0Y et\u00a0al (2020) Pharmacokinetic\/pharmacodynamic analyses of cefiderocol in critically ill patients. Open Forum Infect Dis 7:669\u2013670","journal-title":"Open Forum Infect Dis"}],"container-title":["Medizinische Klinik - Intensivmedizin und Notfallmedizin"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00063-022-00925-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00063-022-00925-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00063-022-00925-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,14]],"date-time":"2023-11-14T01:03:32Z","timestamp":1699923812000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00063-022-00925-5"}},"subtitle":["Neue Therapieoption bei schweren Infektionen durch multiresistente gramnegative Erreger","New therapeutic option for severe infections with multidrug resistant Gram-negative bacteria"],"short-title":[],"issued":{"date-parts":[[2022,8,1]]},"references-count":27,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["925"],"URL":"https:\/\/doi.org\/10.1007\/s00063-022-00925-5","relation":{},"ISSN":["2193-6218","2193-6226"],"issn-type":[{"value":"2193-6218","type":"print"},{"value":"2193-6226","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,1]]},"assertion":[{"value":"4 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 March 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"O.\u00a0Witzke erhielt Forschungszusch\u00fcsse f\u00fcr klinische Studien, Referentenhonorare sowie Honorare und Reisekosten\u00fcbernahmen von den Firmen Amgen, Alexion, Astellas, Basilea, Biotest, Bristol-Myers Squibb, Correvio, Chiesi, Gilead, Hexal, Janssen, Dr. Franz\u00a0K\u00f6hler Chemie, MSD, Novartis, Roche, Pfizer, Sanofi, TEVA und UCB. T.\u00a0Brenner erhielt Honorare f\u00fcr Vortr\u00e4ge, Pr\u00e4sentationen, Manuskripterstellungen oder Bildungsveranstaltungen von den Firmen CSL Behring GmbH, Sch\u00f6chl Medical Education GmbH, Biotest AG, Baxter Deutschland GmbH, Boehringer Ingelheim Pharma GmbH, Astellas Pharma GmbH, B.\u00a0Braun Melsungen AG und MSD Sharp & Dohme GmbH. Er war Teilnehmer des Data Safety Monitoring Board bzw. Advisory Board der Baxter Deutschland GmbH. Er erhielt Forschungsf\u00f6rderungen durch die Deutsche Forschungsgemeinschaft (DFG), die Dietmar Hopp Stiftung, Stiftung Universit\u00e4tsmedizin Essen; die Heidelberger Stiftung Chirurgie und den Innovationsfonds des Gemeinsamen Bundesausschusses (G-BA).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}